WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder (Q63090410)

1

0 references

Borwin Bandelow

2

0 references

Stuart A. Montgomery

4

0 references

David J. Nutt

5

0 references

Ahmed Okasha

6

0 references

Mark H. Pollack

7

0 references

Dan J. Stein

8

0 references

Richard P. Swinson

Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990

9

0 references

publication date

August 2003

0 references

published in

C N S Spectrums

0 references

volume

8

0 references

issue

S1

0 references

page(s)

53-61

0 references

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Psychological treatment of generalised anxiety disorder. A review of the clinical significance of results in outcome studies since 1980.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Paroxetine efficacy in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Long-term pharmacological treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Pharmacologic treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: II. Pharmacotherapy of anxiety disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

The assessment of anxiety states by rating

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

PET in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

The nature and duration of treatment for GAD.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Generalized anxiety disorder. Longitudinal course and pharmacologic treatment.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Long-term Treatment of Anxiety and Risk of Withdrawal

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Buspirone: future directions

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

The epidemiology of generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Distressed high utilizers of medical care. DSM-III-R diagnoses and treatment needs

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Diazepam: how much better than placebo?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

An overview of generalized anxiety disorder: disease state--appropriate therapy

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Cost of anxiety disorders: impact of comorbidity.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Recent developments in the psychopharmacology of anxiety disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

The Clinical Course and Long-Term Management of Generalized Anxiety Disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021

Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900006945

7 January 2021